RARE PHOTOS: Eton pharmaceuticals | Rare Historical Photos

High PEG ratios indicate that many defensive stocks in health care and consumer staples trade at stretched valuations. With earnings growth lagging price momentum, three stand out as candidates for profit-taking while the market’s risk appetite begins to shift.

Summary Eton Pharmaceuticals (ETON) has shown exceptional price appreciation, gaining 224.93% since a Trend Seeker buy signal on 7/17, supported by strong technical indicators. The company focuses on developing and commercializing pharmaceutical products for rare diseases, with significant revenue and earnings growth expected in the coming years. Barchart's technical indicators...

Eton Pharmaceuticals Inc (NASDAQ:ETON) has appointed James Gruber as Chief Financial Officer effective immediately. He succeeds Wilson Troutman, who is retiring. Mr. Troutman will remain with the company through May to ensure a smooth transition. Mr. Gruber, most recently, was the U.S. Controller at Horizon Therapeutics (NASDAQ:HZNP) for seven years, where he oversaw…